<DOC>
	<DOCNO>NCT01659021</DOCNO>
	<brief_summary>This study evaluate effect addition idelalisib ( GS-1101 ) ofatumumab progression-free survival ( PFS ) participants previously treat chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Efficacy Safety Idelalisib ( GS-1101 ; CAL-101 ) Combination With Ofatumumab Previously Treated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Key Adults previously treat recurrent CLL measurable lymphadenopathy Require therapy CLL Have experience CLL progression &lt; 24 month since completion last prior therapy Have disease refractory ofatumumab Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CLL</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>GS-1101</keyword>
	<keyword>CAL-101</keyword>
	<keyword>Ofatumumab</keyword>
</DOC>